Inspire Investing LLC Purchases 9,484 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Inspire Investing LLC boosted its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 44.5% in the 4th quarter, HoldingsChannel.com reports. The firm owned 30,792 shares of the company’s stock after buying an additional 9,484 shares during the quarter. Inspire Investing LLC’s holdings in Syndax Pharmaceuticals were worth $407,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Syndax Pharmaceuticals during the 2nd quarter valued at $27,000. Values First Advisors Inc. acquired a new position in Syndax Pharmaceuticals in the third quarter valued at about $30,000. Quantbot Technologies LP bought a new position in Syndax Pharmaceuticals during the third quarter worth about $49,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Syndax Pharmaceuticals by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock worth $58,000 after buying an additional 541 shares during the period. Finally, Quarry LP increased its stake in shares of Syndax Pharmaceuticals by 75.0% in the 2nd quarter. Quarry LP now owns 6,125 shares of the company’s stock valued at $126,000 after acquiring an additional 2,625 shares during the last quarter.

Syndax Pharmaceuticals Stock Down 1.1 %

NASDAQ SNDX opened at $14.25 on Friday. Syndax Pharmaceuticals, Inc. has a 12-month low of $12.06 and a 12-month high of $25.34. The firm’s 50 day moving average is $14.39 and its 200-day moving average is $18.07. The company has a market capitalization of $1.22 billion, a PE ratio of -3.93 and a beta of 0.89.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.13) by $0.15. The business had revenue of $12.50 million for the quarter, compared to the consensus estimate of $9.16 million. During the same period last year, the firm earned ($0.73) earnings per share. As a group, sell-side analysts expect that Syndax Pharmaceuticals, Inc. will post -3.71 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on SNDX. UBS Group started coverage on shares of Syndax Pharmaceuticals in a report on Thursday, October 24th. They issued a “buy” rating and a $37.00 target price on the stock. The Goldman Sachs Group lifted their target price on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. HC Wainwright restated a “buy” rating and issued a $51.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, December 10th. StockNews.com cut Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 23rd. Finally, Stifel Nicolaus raised their target price on shares of Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a “buy” rating in a report on Monday, October 14th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $36.20.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).